...
首页> 外文期刊>Journal of the Medical Association of Thailand =: Chotmaihet thangphaet >Randomized controlled study of probiotics containing Lactobacillus casei (Shirota strain) for prevention of ventilator-associated pneumonia.
【24h】

Randomized controlled study of probiotics containing Lactobacillus casei (Shirota strain) for prevention of ventilator-associated pneumonia.

机译:含有干酪乳杆菌(Shirota菌株)的益生菌预防呼吸机相关性肺炎的随机对照研究。

获取原文
获取原文并翻译 | 示例

摘要

To evaluate the efficacy ofprobiotics, Lactobacillus casei (Shirvta strain), in reducing the incidence ofventilator- associated pneumonia (VAP) in medical patients who received mechanical ventilation at Siriraj Hospital.A prospective, randomized, open-label controlled trial was conducted in 150 adult hospitalized patients in medical wards who were expected to receive mechanical ventilation for 72 hours or longer: The patients were randomized to the probiotics group or the control group. All patients received regular care for mechanical ventilation. The patients in the probiotics group received 80 ml of Lactobacillus casei (Shirota strain) for oral care after having standard oral care once daily and additional 80 ml of the aforementionedfermented dairy product was given via enteralfeeding once daily. The primary outcomes were incidence of VAP and incidence rate of VAP episodes per 1,000 ventilator-days. The secondary outcomes were length ofhospital stay, mortality at day 28 and 90, incidence ofdiarrhea, andpresence of resistant bacteria in oropharyngeal and rectal swab samples taken from the patients at baseline, day 7 and day 28 after enrollment.The baseline characteristics of the patients in the probiotics group (75) and the control group (75) were not significantly different. The patients in the probiotics group were less likely to develop VAP compared with the control group (24% vs. 29.3%, p = 0.46), respectively. The incidence rates of VAP in the probiotics and control groups were 22.64 and 30.22 episodes per 1,000 ventilator-days, respectively (p = 0.37). A trend of lower prevalence of some resistant bacteria cultured from oropharyngeal swabs in the probiotics group than that in the control group was observed. Overall 28- and 90-day mortality and length of hospital stay of the patients in both groups were not significantly different.Administration of probiotics containing Lactobacillus casei (Shirota strain) has a tendency to reduce the incidence of VAP and colonization with resistant bacteria in oropharyngeal cavity without significant effects on mortality and length of hospital stay.
机译:为了评估益生菌干酪乳杆菌(Shirvta株)在降低Siriraj医院接受机械通气的医学患者的通气相关肺炎(VAP)发病率方面的作用。这项针对150名成人进行的前瞻性,随机,开放标签对照试验预期在病房中接受机械通气72小时或更长时间的住院患者:将患者随机分为益生菌组或对照组。所有患者均接受定期机械通气护理。益生菌组的患者每天接受一次标准口腔护理后,接受80毫升干酪乳杆菌(Shirota菌株)进行口腔护理,并且每天通过肠内喂食再给予80毫升上述发酵乳制品。主要结局为VAP发生率和每1000呼吸机天VAP发作的发生率。次要结局为入院后第7天和第28天从患者采集的口咽和直肠拭子样本中的住院时间,住院28天和90天的死亡率,腹泻发生率以及耐药菌的存在。益生菌组(75)和对照组(75)没有显着差异。与对照组相比,益生菌组患者发生VAP的可能性较小(分别为24%和29.3%,p = 0.46)。益生菌和对照组中VAP的发生率分别为每1000呼吸机天22.64次和30.22次发作(p = 0.37)。在益生菌组中观察到口咽拭子培养的一些耐药细菌的流行率比对照组低。两组患者的28天和90天的总死亡率和住院时间没有显着差异。含干酪乳杆菌(Shirota菌株)的益生菌的施用有降低VAP发生率和在口咽中产生耐药菌的趋势。腔对死亡率和住院时间没有明显影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号